Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194375 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
A Phase 2 study, sponsored by Dow Pharmaceutical Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01194375: Completed Phase 2 study, sponsored by Dow Pharmaceutical Sciences.
NCT01194375 is a Phase 2 study that has completed, run by Dow Pharmaceutical Sciences. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194375, a Phase 2 study, has completed, sponsored by Dow Pharmaceutical Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Low Strength IDP-107
- DRUG High Strength IDP-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01194375 record still lists
NCT01194375 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01194375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01194375 about?
NCT01194375 is a clinical study titled "A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris". The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
What is the current status of trial NCT01194375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01194375?
The interventions under investigation include: Placebo (DRUG), Low Strength IDP-107 (DRUG), High Strength IDP-107 (DRUG).
Who is sponsoring clinical trial NCT01194375?
This trial is sponsored by Dow Pharmaceutical Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01194375's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia